乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析

目的 探讨18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67（一种增殖细胞核抗原）表达水平的相关性。 方法 18例经病理确诊的原发性乳腺癌患者术前行18F-FDG PET/CT和3.0T MRI联合显像，对显像结果进行评分并与Ki-67的表达水平进行相关性分析。联合显像和术后病理标本的免疫组化检测在一周内完成。 结果 ① 乳腺癌最大标准化摄取值与Ki-67的表达水平呈正相关（r=0.473，P＜0.05）；②PET/CT和3.0T MRI联合显像评分与Ki-67的表达水平呈明显正相关（r=0.674，P＜0.01）。 结论 18F-FDG PET/CT和3.0T MRI联合显像在乳腺癌的预后判断中可能具有重要的潜在价值。

Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer

Objective To explore the correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67(proliferating cell nuclear antigen)in breast cancer. Methods A retrospective study was carried out in eighteen patients with pathologically confirmed primary breast cancer, who underwent both 18F-FDG PET/CT and 3.0T MRI examinations before operation. The interval between immunohistochemisty and combined imaging examinations was not more than one week after operation. The correlations between maximum standardized uptake value(SUV_max) as well as the score of combined imaging modalities and the expression level of Ki-67 were analyzed. Results ①A positive correlation between SUV_max and expression level of Ki-67 was demonstrated in breast cancer lesions(r=0.473, P < 0.05). ②A significantly positive correlation between the score of combined imaging modalities and the expression level of Ki-67 was also noted(r=0.674, P < 0.01). Conclusion Tumor proliferation can be reflected by the combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI, indicating a potential role in predicting prognosis of breast cancer.